Donor and recipient gastrointestinal tracts and their microbiomes are represented on the cover as converging pipes, demonstrating the interplay between the microbial communities after FMT, described in Bork et al.

Patient safety needs innovation

Advances in the applications of artificial intelligence and other technologies in health and medicine require rethinking of what patient safety means.

Editorial

Announcements

  • NMED DEI

    Nature Medicine, in partnership with Nature Communications and Communications Medicine, is excited to announce a call for submission of innovative clinical research on the prevention, detection, diagnostic and treatment of cancer. Click here to learn how to submit your work.

  • MedInVirtualAge

    Organized by Nature Medicine, this online conference will focus on health care delivery via remote technologies — connecting individuals and health professionals, bringing care to low-resource settings, and ensuring equal access for all. October 4-6, 2022. Registration is free. Abstract submission deadline is September 8, 2022.

  • Crab, the avatar of cancer.

    Read about the latest advances in translational and clinical research, selected by the Nature Medicine editorial team.

Nature Medicine is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.

Advertisement

    • CAR-mediated trogocytosis contributes to dysfunction of natural killer (NK) cells by promoting fratricide and is an important mechanism of relapse after CAR-NK cell therapy. This problem can be overcome using a dual-CAR strategy that incorporates a dominant-negative signal to prevent NK cell fratricide and exhaustion, while sparing the CAR-activating signal against tumor targets.

      Research Briefing
    • Following a single infusion of CD19-targeting CAR T cells, five patients with SLE showed reduction in disease activity and disease markers; long-term follow-up of these patients and larger trials are now key priorities.

      • Jane E. Salmon
      News & Views
    • Early identification of at-risk people is critical in disease prevention, but current screening approaches are resource intensive and are often restricted to one disease at a time. We show how nuclear magnetic resonance (NMR) spectroscopy–derived metabolomics profiles can be used to predict multi-disease risk for the onset of 24 common conditions.

      Research Briefing
    • To accelerate the development of T cell–based immunotherapies that are effective for more patients with cancer, there is an urgent need to decipher the precise attributes of the ideal therapeutic T cell. In March 2021, the Parker Institute of Cancer Immunotherapy and 10x Genomics partnered to bring together a group of T cell immunotherapy researchers and single-cell-technology innovators for a day’s workshop. Participants evaluated the current cutting edge of knowledge, identified areas for focused technology development, and put forward a call to action to the field. Insights were provided on how to best leverage single-cell technologies and key areas for future development were proposed — with the goal of facilitating a better understanding of T cell research and translation of this research into effective cancer immunotherapies. The key points of discussion that emerged from this workshop are summarized here.

      • Samantha L. Bucktrout
      • Nicholas E. Banovich
      • Abbey Cutchin
      Meeting Report

Nature Careers

Events

Jobs

Advertisement